> ## Content Index
> Fetch the complete content index at: https://www.edgewisely.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Top 7 AI Drug Discovery Companies in 2026
- URL: https://www.edgewisely.com/top-7-ai-drug-discovery-companies-in-2026/
- Published: 2026-09-01T06:31:56.000Z
- Updated: 2026-09-01T06:31:56.000Z
- Description: Who this is for: pharma partnerships teams, biotech investors, and operators tracking which AI-native drug discovery platforms are actually moving molecules into clinical trials, not just publishing benchmarks.
- Author: John Karpentar
- Tags: Roundups, Healthcare

**Who this is for: pharma partnerships teams, biotech investors, and operators tracking which AI-native drug discovery platforms are actually moving molecules into clinical trials — not just publishing benchmarks.**

AI drug discovery moved from a research narrative to a clinical one in 2026\. Isomorphic Labs got its first AI-designed molecule, ISM8969, cleared by the FDA for human trials in January and closed a $2.1 billion Series B in May. Insilico Medicine now has a dozen programs with IND clearance and signed a strategic deal with Takeda in July. Recursion has logged more than $500 million in upfront and milestone payments across its partnerships. The companies below are the ones with real pipeline progress, disclosed deals, or both — not just a platform pitch deck.

## How we picked these

We prioritized companies with a proprietary AI platform actually generating drug candidates, at least one disclosed pharma partnership or public pipeline with named targets, and verifiable 2025–2026 progress (funding, IND clearances, or clinical milestones). We excluded pure computational-biology tool vendors that don't run their own drug programs and companies whose only public evidence is a funding announcement with no platform detail. Ranking weighs clinical and partnership progress first, platform differentiation second.

## Quick comparison

| Company                                                                        | Best for                                                                      | Deployment model                                               | Business model                                                              |
| ------------------------------------------------------------------------------ | ----------------------------------------------------------------------------- | -------------------------------------------------------------- | --------------------------------------------------------------------------- |
| [Recursion Pharmaceuticals](https://www.recursion.com/?ref=edgewisely.com)     | Public-company scale and phenotypic screening data                            | In-house pipeline + platform licensing                         | Public company (Nasdaq: RXRX); pharma partnerships + own pipeline           |
| [Isomorphic Labs](https://www.isomorphiclabs.com/?ref=edgewisely.com)          | AlphaFold-derived structure-based drug design                                 | In-house pipeline + pharma collaborations                      | Private (Alphabet spin-off); partnership deals + Series B funding           |
| [Insilico Medicine](https://insilico.com/?ref=edgewisely.com)                  | Breadth — target discovery through clinical-stage programs                    | End-to-end Pharma.AI platform, own pipeline + licensing        | Private; software revenue + partnership deals + own clinical assets         |
| [Xaira Therapeutics](https://www.xaira.com/?ref=edgewisely.com)                | Protein and biologics design at start-up scale with elite scientific founders | In-house pipeline                                              | Private; $1B Series A, no disclosed partnership revenue yet                 |
| [Iambic Therapeutics](https://www.iambic.ai/?ref=edgewisely.com)               | Small-molecule oncology with fast IND timelines                               | In-house pipeline + pharma collaborations                      | Private; VC funding + Takeda/Bayer partnerships                             |
| [Genesis Therapeutics](https://www.genesistherapeutics.ai/?ref=edgewisely.com) | Structure-based small-molecule design licensed to major pharma                | Platform licensing to pharma partners                          | Private; upfront + milestone payments from Incyte, Gilead, Lilly, Genentech |
| [Absci Corporation](https://www.absci.com/?ref=edgewisely.com)                 | Generative biologics design paired with wet-lab validation                    | Integrated Drug Creation platform, own pipeline + partnerships | Public company (Nasdaq: ABSI); partnerships + own pipeline                  |

*As of September 2026\. Deal values and funding figures are as publicly disclosed; several partnerships include undisclosed milestone components.*

## 1\. Recursion Pharmaceuticals

[Recursion](https://www.recursion.com/?ref=edgewisely.com) built its platform on large-scale phenotypic screening — imaging how cells respond to millions of perturbations and using that data to train models that predict biological relationships. After merging with Exscientia in November 2024, it operates as a vertically integrated, publicly traded company (Nasdaq: RXRX) with both its own pipeline and partnership revenue. It reports five differentiated clinical programs advancing in 2026, including its first AI-enabled clinical proof of concept, and more than $500 million in upfront and milestone payments earned across partners including Sanofi.

**Best for:** organizations that want a public, financially transparent AI drug discovery partner with the largest disclosed phenotypic dataset in the category.

**Pros** \- Publicly traded, so financials, pipeline updates, and milestone payments are disclosed on a regular SEC reporting cadence - Large proprietary phenotypic imaging dataset that's difficult for smaller competitors to replicate - Vertically integrated after the Exscientia merger, combining biology, chemistry, and clinical development - More than $500 million in earned milestone and upfront payments demonstrates partners are renewing and expanding deals

**Cons** \- As a public company, stock performance and investor patience are tied to clinical readouts, which introduces pressure not present at private-company competitors - Its own analysts and press coverage note the company is still "testing investor patience" on translating platform breadth into approved drugs - Phenotypic screening approaches face open scientific debate over how well cell-imaging signals generalize to human clinical outcomes - Heavier reliance on partnership milestone revenue than a company with an already-approved product

## 2\. Isomorphic Labs

[Isomorphic Labs](https://www.isomorphiclabs.com/?ref=edgewisely.com) is the Alphabet-backed spin-off from Google DeepMind that applies AlphaFold's protein-structure prediction to drug design. Its "IsoDDE" drug-discovery engine integrates protein-ligand interaction modeling, binding affinity prediction, and binding-pocket identification. In January 2026 its first AI-designed molecule, ISM8969, was cleared by the FDA for human trials in oncology, and in May the company closed a $2.1 billion Series B led by Thrive Capital with participation from Alphabet's GV, MGX, Temasek, and others.

**Best for:** partners who want the deepest tie to protein-structure prediction research and the largest disclosed funding round in the category.

**Pros** \- Direct lineage from AlphaFold, the most externally validated structure-prediction model in computational biology - $2.1 billion Series B gives it one of the largest capital cushions of any AI-native biotech - First AI-designed molecule (ISM8969) cleared for human trials, a genuine clinical milestone rather than a preclinical claim - Alphabet and DeepMind backing brings compute and research talent most competitors can't match

**Cons** \- Still very early clinically — one molecule in human trials is a meaningful first step, not proof the platform generalizes across disease areas - Close ties to Alphabet mean its long-term independence and governance are less clear than a fully standalone biotech - Limited public detail on its broader pipeline beyond the oncology and immunology programs disclosed so far - As a private company, financial terms of partnerships and detailed trial data are not disclosed with SEC-level transparency

## 3\. Insilico Medicine

[Insilico Medicine](https://insilico.com/?ref=edgewisely.com) runs Pharma.AI, an integrated platform spanning target discovery (PandaOmics), molecule generation (Chemistry42), and LLM-based reasoning. As of early 2026 it reports more than 40 internal and partnered drug programs, 24 of them publicly disclosed, with 12 having received IND clearance for clinical trials — a scale of disclosed pipeline breadth that's unusual in the category. In July 2026 it signed a strategic collaboration with Takeda, adding to a partner roster that already includes 13 of the top 20 global pharmaceutical companies and cumulative deal value the company puts at $4.6 billion.

**Best for:** pharma partners who want end-to-end platform coverage from target identification through IND-ready candidates, with the broadest disclosed pipeline in the category.

**Pros** \- Widest disclosed pipeline breadth of any company on this list — 24 publicly disclosed programs, 12 with IND clearance - End-to-end platform (target discovery, molecule design, clinical reasoning) rather than a single-module tool - Commercial traction with 13 of the top 20 global pharma companies as software customers - Reports meaningfully compressed discovery timelines (12–18 months to preclinical candidate versus an industry norm of 2.5–4 years) on its disclosed programs

**Cons** \- Compressed-timeline and success-rate claims come primarily from the company's own disclosures rather than independent third-party validation - Breadth across three separate platform modules (PandaOmics, Chemistry42, MMAI Gym) adds integration complexity compared to a single-focus platform - As a private company, deal economics behind the disclosed $4.6 billion cumulative figure are not independently auditable - Operates across multiple jurisdictions (originally US-founded, now with significant Hong Kong and mainland China operations), which can complicate due diligence for some Western partners

## 4\. Xaira Therapeutics

[Xaira Therapeutics](https://www.xaira.com/?ref=edgewisely.com) launched in April 2024 with more than $1 billion in funding — the largest initial commitment in Arch Venture Partners' history — co-founded by Nobel laureate David Baker (2024 Chemistry Prize, protein design) and CEO Marc Tessier-Lavigne, former Stanford president and Genentech CSO. The company applies foundation models to protein and small-molecule design across oncology, immunology, and neurology, with assets expected to enter IND-enabling studies from 2026.

**Best for:** partners betting on scientific pedigree and foundation-model protein design at a well-capitalized early-stage company.

**Pros** \- Co-founded by a Nobel Prize-winning protein designer, giving it unusually deep scientific credibility for a two-year-old company - $1 billion in initial funding from Arch Venture Partners, Foresite Capital, Sequoia, NEA, and others provides a long runway without near-term fundraising pressure - Applies foundation-model approaches to both small-molecule and biologic modalities, rather than specializing in one - Leadership combines academic research pedigree (Baker) with large-organization execution experience (Tessier-Lavigne at Genentech and Stanford)

**Cons** \- No disclosed clinical-stage assets yet as of 2026 — pipeline progress is earlier-stage than Recursion, Insilico, or Isomorphic Labs - No disclosed major pharma partnership revenue, unlike Genesis, Iambic, or Insilico, so the business model beyond its own pipeline is less proven - Founding leadership includes figures who have faced public scrutiny in other contexts, which some partners weigh in due diligence - At a reported $4 billion valuation against $1 billion raised, expectations for platform output are high relative to current public disclosures

## 5\. Iambic Therapeutics

[Iambic Therapeutics](https://www.iambic.ai/?ref=edgewisely.com) is a clinical-stage biotech combining proprietary AI models — including Enchant and NeuralPLexer for multimodal endpoint prediction — with automated, high-throughput wet-lab experimentation. Its lead program, IAM1363, targeting HER2 for HER2-positive cancers, is in Phase 1/1b. In 2026 it signed collaborations with both Takeda (February, oncology and GI/inflammation) and Bayer (June), and it closed a $50 million Series B extension in late 2025 to fund additional clinical oncology programs.

**Best for:** partners looking for a clinical-stage small-molecule oncology platform with fast internal IND timelines and multiple active pharma deals.

**Pros** \- Already has a program in Phase 1/1b clinical trials (IAM1363), ahead of several larger-funded competitors on this list - Two major pharma collaborations signed in a single year (Takeda, Bayer) signal ongoing commercial validation of the platform - Tight feedback loop between AI prediction (Enchant, NeuralPLexer) and automated experimentation, rather than AI-only design handed to a separate wet lab - Focused disease-area strategy (oncology, with GI/inflammation expansion via Takeda) rather than spreading across many indications at once

**Cons** \- Far smaller balance sheet than Xaira, Isomorphic Labs, or Recursion — its $50 million Series B extension is modest next to competitors' nine- and ten-figure raises - Pipeline beyond the lead HER2 program is still largely preclinical (IAM-K1, IAM-C1) - As a private company, financial terms of the Takeda and Bayer collaborations are not fully disclosed - Success of the platform is still resting heavily on the outcome of one clinical-stage asset

## 6\. Genesis Therapeutics

[Genesis Therapeutics](https://www.genesistherapeutics.ai/?ref=edgewisely.com) runs GEMS (Genesis Exploration of Molecular Space), a platform combining 3D structure prediction (its "Pearl" model), deep learning predictive models, molecular simulation, and chemically aware language models for small-molecule discovery and optimization. Rather than running a large in-house clinical pipeline, Genesis has built its business primarily on platform licensing deals with major pharmaceutical companies: Incyte expanded its collaboration with an $80 million upfront payment in May 2026, and Genesis has separate deals with Gilead, Eli Lilly (potentially worth up to $670 million across five targets), and Genentech.

**Best for:** pharma partners specifically seeking small-molecule structure-based design, licensed rather than built in-house.

**Pros** \- Diversified partnership base across four major pharma companies (Incyte, Gilead, Lilly, Genentech) rather than dependence on a single deal - The Incyte expansion is explicitly framed as supporting large-scale foundation-model training on partner experimental data — an unusually deep technical integration for a licensing deal - Focused specialization in small-molecule structure-based design rather than spreading across biologics and multiple modalities - Repeat and expanded deals (Incyte upsizing its collaboration) suggest partners are seeing enough value to increase commitment

**Cons** \- Business model depends heavily on pharma partners continuing to renew and expand licensing deals; it does not appear to run a large disclosed pipeline fully of its own - As a private company, actual milestone realization behind headline deal values (e.g., the up-to-$670 million Lilly figure) is not verifiable — these are typically "biobucks" ceilings, not guaranteed payments - Less public brand visibility than Recursion, Isomorphic Labs, or Insilico Medicine, despite comparable deal scale - Limited disclosed information on clinical-stage progress of molecules discovered through its partnerships

## 7\. Absci Corporation

[Absci](https://www.absci.com/?ref=edgewisely.com) is a publicly traded (Nasdaq: ABSI) company built around generative AI for biologics, pairing its models with a synthetic biology data engine in a continuous design-and-validate loop it calls Integrated Drug Creation. Alongside partnership work, it runs its own pipeline, including ABS-201, a candidate for androgenetic alopecia also being investigated for endometriosis. As of its most recent disclosures, the company projects its cash runway extends into the second half of 2028.

**Best for:** partners focused specifically on generative design of biologics (antibodies and proteins) rather than small molecules.

**Pros** \- Publicly traded, giving standard SEC-level financial and pipeline disclosure - Explicit closed-loop design between generative AI and wet-lab validation, rather than AI-only design handed off externally - Disclosed cash runway into second half of 2028 provides unusual clarity on financial stability for a clinical-stage AI biotech - Global R&D footprint (Vancouver WA headquarters, New York and Serbia AI labs, Switzerland innovation center) supports both AI and wet-lab talent access

**Cons** \- Its lead disclosed internal program (ABS-201, hair regrowth/endometriosis) is a narrower and lower-profile indication than the oncology focus of several competitors - As with all clinical-stage public biotechs, share price is sensitive to trial readouts, and returns depend on approvals years away - Smaller partnership roster disclosed publicly compared to Genesis or Insilico Medicine - Focus on biologics/antibody generative design means it doesn't compete directly on small-molecule discovery, narrowing its addressable partnership pool

## How to choose

If you want the most disclosed pipeline breadth and commercial traction with top-20 pharma, Insilico Medicine's Pharma.AI has the most public evidence. If capital depth and structural biology pedigree matter most, Isomorphic Labs and Xaira are the best-funded, though both are earlier on translating that capital into clinical assets. If you specifically need small-molecule structure-based design licensed into your own pipeline, Genesis Therapeutics has the cleanest multi-partner track record. For biologics-specific generative design, Absci is the clearest public option. And if you want a program already in the clinic today rather than a platform promise, Iambic's Phase 1/1b HER2 asset and Recursion's five active clinical programs are the most concrete near-term bets.

## Frequently Asked Questions

### Has any AI-discovered drug reached approval?

As of September 2026, no drug candidate discovered primarily through an AI-native platform on this list has reached full regulatory approval. Several — including Isomorphic Labs' ISM8969 and Iambic's IAM1363 — have entered human clinical trials, which is the furthest most of these programs have progressed publicly.

### What's the difference between a platform company and a pipeline company in AI drug discovery?

Platform companies like Genesis Therapeutics primarily license their AI discovery engine to pharma partners for a fee plus milestones. Pipeline companies like Recursion, Isomorphic Labs, and Absci run their own drug candidates through development, sometimes alongside partnership deals. Several companies, like Insilico Medicine, do both simultaneously.

### Why did Recursion merge with Exscientia?

Recursion completed its business combination with Exscientia in November 2024, creating a vertically integrated company that combines Recursion's phenotypic screening data with Exscientia's chemistry and clinical-development capabilities under one publicly traded entity.

### Are "biobucks" partnership figures the actual amount paid?

No. Deal values like Genesis Therapeutics' up-to-$670 million agreement with Eli Lilly are typically milestone ceilings covering multiple targets and development stages — companies usually receive a smaller upfront payment, with the bulk contingent on hitting future clinical and regulatory milestones that may never be reached.

### Which of these companies are publicly traded?

Recursion Pharmaceuticals (Nasdaq: RXRX) and Absci Corporation (Nasdaq: ABSI) are publicly traded. Isomorphic Labs, Insilico Medicine, Xaira Therapeutics, Iambic Therapeutics, and Genesis Therapeutics are privately held as of September 2026.

---

**Editor's note — sources:** Recursion pipeline and financial disclosures via SEC 8-K filings and ir.recursion.com; Isomorphic Labs funding and clinical milestone via allsci.com, intuitionlabs.ai, and company statements; Insilico Medicine pipeline and Takeda deal via insilico.com news releases and pharmaphorum; Xaira Therapeutics funding and founding via fiercebiotech.com and drugdiscoverytrends.com; Iambic Therapeutics pipeline and partnerships via iambic.ai and medcitynews.com; Genesis Therapeutics deals via fiercebiotech.com and investor.incyte.com; Absci pipeline and financials via SEC 8-K filings and investors.absci.com.